Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

Authors: Chariya Hahnvajanawong, Wareeporn Wattanawongdon, Chariya Chomvarin, Natthinee Anantachoke, Sakawrat Kanthawong, Banchob Sripa, Vichai Reutrakul

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.

Methods

KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.

Results

Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.

Conclusion

The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006, 98: 873-5. 10.1093/jnci/djj234.CrossRefPubMed Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006, 98: 873-5. 10.1093/jnci/djj234.CrossRefPubMed
2.
go back to reference West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006, 94: 1751-8. 10.1038/sj.bjc.6603127.CrossRefPubMedCentralPubMed West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006, 94: 1751-8. 10.1038/sj.bjc.6603127.CrossRefPubMedCentralPubMed
3.
go back to reference Olnes MJ, Erlich R: A review and update on cholangiocarcinoma. Oncology. 2004, 66: 167-79. 10.1159/000077991.CrossRefPubMed Olnes MJ, Erlich R: A review and update on cholangiocarcinoma. Oncology. 2004, 66: 167-79. 10.1159/000077991.CrossRefPubMed
4.
go back to reference Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005, 16 (Suppl 2): ii93-6.PubMed Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005, 16 (Suppl 2): ii93-6.PubMed
5.
go back to reference Raghavan D, Koczwara B, Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer. 1997, 33: 566-74. 10.1016/S0959-8049(96)00510-2.CrossRefPubMed Raghavan D, Koczwara B, Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer. 1997, 33: 566-74. 10.1016/S0959-8049(96)00510-2.CrossRefPubMed
6.
go back to reference Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979, 91: 710-7. 10.7326/0003-4819-91-5-710.CrossRefPubMed Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979, 91: 710-7. 10.7326/0003-4819-91-5-710.CrossRefPubMed
7.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
8.
go back to reference Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol. 2001, 54: 927-32. 10.1136/jcp.54.12.927.CrossRefPubMedCentralPubMed Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol. 2001, 54: 927-32. 10.1136/jcp.54.12.927.CrossRefPubMedCentralPubMed
9.
go back to reference Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ: Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology. 1997, 26: 884-90. 10.1002/hep.510260413.CrossRefPubMed Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ: Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology. 1997, 26: 884-90. 10.1002/hep.510260413.CrossRefPubMed
10.
go back to reference Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64: 3517-24. 10.1158/0008-5472.CAN-03-2770.CrossRefPubMed Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64: 3517-24. 10.1158/0008-5472.CAN-03-2770.CrossRefPubMed
11.
go back to reference Namwat N, Amimanan P, Loilome W, Jearanaikoon P, Sripa B, Bhudhisawasdi V, Tassaneeyakul W: Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy. 2008, 54: 343-51. 10.1159/000151541.CrossRefPubMed Namwat N, Amimanan P, Loilome W, Jearanaikoon P, Sripa B, Bhudhisawasdi V, Tassaneeyakul W: Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy. 2008, 54: 343-51. 10.1159/000151541.CrossRefPubMed
12.
go back to reference Pinlaor S, Hiraku Y, Yongvanit P, Tada-Oikawa S, Ma N, Pinlaor P, Sithithaworn P, Sripa B, Murata M, Oikawa S, Kawanishi S: iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int J Cancer. 2006, 119: 1067-72. 10.1002/ijc.21893.CrossRefPubMed Pinlaor S, Hiraku Y, Yongvanit P, Tada-Oikawa S, Ma N, Pinlaor P, Sithithaworn P, Sripa B, Murata M, Oikawa S, Kawanishi S: iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int J Cancer. 2006, 119: 1067-72. 10.1002/ijc.21893.CrossRefPubMed
13.
go back to reference Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000, 92: 1295-302. 10.1093/jnci/92.16.1295.CrossRefPubMed Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000, 92: 1295-302. 10.1093/jnci/92.16.1295.CrossRefPubMed
14.
go back to reference Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V, Tassaneeyakul W: Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005, 11: 2748-53.CrossRefPubMedCentralPubMed Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V, Tassaneeyakul W: Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005, 11: 2748-53.CrossRefPubMedCentralPubMed
15.
go back to reference Courtois A, Payen L, Lagadic D, Guillouzo A, Fardel O: Evidence for a multidrug resistance-associated protein 1 (MRP1)-related transport system in cultured rat liver biliary epithelial cells. Life Sci. 1999, 64: 763-74. 10.1016/S0024-3205(98)00618-3.CrossRefPubMed Courtois A, Payen L, Lagadic D, Guillouzo A, Fardel O: Evidence for a multidrug resistance-associated protein 1 (MRP1)-related transport system in cultured rat liver biliary epithelial cells. Life Sci. 1999, 64: 763-74. 10.1016/S0024-3205(98)00618-3.CrossRefPubMed
16.
go back to reference Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B: Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008, 262: 214-22. 10.1016/j.canlet.2007.12.004.CrossRefPubMed Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B: Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008, 262: 214-22. 10.1016/j.canlet.2007.12.004.CrossRefPubMed
17.
go back to reference Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei FF, Rong JJ, You QD, Guo QL: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology. 2009, 256: 135-40. 10.1016/j.tox.2008.11.014.CrossRefPubMed Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei FF, Rong JJ, You QD, Guo QL: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology. 2009, 256: 135-40. 10.1016/j.tox.2008.11.014.CrossRefPubMed
18.
go back to reference Han QB, Xu HX: Caged Garcinia xanthones: development since 1937. Curr Med Chem. 2009, 16: 3775-96. 10.2174/092986709789104993.CrossRefPubMed Han QB, Xu HX: Caged Garcinia xanthones: development since 1937. Curr Med Chem. 2009, 16: 3775-96. 10.2174/092986709789104993.CrossRefPubMed
19.
go back to reference Zhao L, Guo QL, You QD, Wu ZQ, Gu HY: Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004, 27: 998-1003. 10.1248/bpb.27.998.CrossRefPubMed Zhao L, Guo QL, You QD, Wu ZQ, Gu HY: Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004, 27: 998-1003. 10.1248/bpb.27.998.CrossRefPubMed
20.
go back to reference Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, Gu HY, Zhao L, Lu N, Qi Q, Liu W, Wang XT, Guo QL: Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biomed Pharmacol. 2008, 75: 1083-92. Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, Gu HY, Zhao L, Lu N, Qi Q, Liu W, Wang XT, Guo QL: Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biomed Pharmacol. 2008, 75: 1083-92.
21.
go back to reference Guo QL, Lin SS, You QD, Gu HY, Yu J, Zhao L, Qi Q, Liang F, Tan Z, Wang XT: Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 2006, 78: 1238-45. 10.1016/j.lfs.2005.06.046.CrossRefPubMed Guo QL, Lin SS, You QD, Gu HY, Yu J, Zhao L, Qi Q, Liang F, Tan Z, Wang XT: Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 2006, 78: 1238-45. 10.1016/j.lfs.2005.06.046.CrossRefPubMed
22.
go back to reference Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X: Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis. 2007, 28: 632-8.CrossRefPubMed Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X: Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis. 2007, 28: 632-8.CrossRefPubMed
23.
go back to reference Qi Q, Gu HY, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang XT, Guo QL: Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl). 2008, 86: 1367-77. 10.1007/s00109-008-0398-z.CrossRef Qi Q, Gu HY, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang XT, Guo QL: Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl). 2008, 86: 1367-77. 10.1007/s00109-008-0398-z.CrossRef
24.
go back to reference Qin YX, Meng LH, Hu CX, Duan WH, Zuo ZL, Lin LP, Zhang XW, Ding J: Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther. 2007, 6: 2429-40. 10.1158/1535-7163.MCT-07-0147.CrossRefPubMed Qin YX, Meng LH, Hu CX, Duan WH, Zuo ZL, Lin LP, Zhang XW, Ding J: Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther. 2007, 6: 2429-40. 10.1158/1535-7163.MCT-07-0147.CrossRefPubMed
25.
go back to reference Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A. 1991, 88: 4328-32. 10.1073/pnas.88.10.4328.CrossRefPubMedCentralPubMed Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A. 1991, 88: 4328-32. 10.1073/pnas.88.10.4328.CrossRefPubMedCentralPubMed
26.
go back to reference Yang Y, Yang L, You QD, Nie FF, Gu HY, Zhao L, Wang XT, Guo QL: Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 2007, 256: 259-66. 10.1016/j.canlet.2007.06.014.CrossRefPubMed Yang Y, Yang L, You QD, Nie FF, Gu HY, Zhao L, Wang XT, Guo QL: Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 2007, 256: 259-66. 10.1016/j.canlet.2007.06.014.CrossRefPubMed
27.
go back to reference Guo QL, Qi Q, You QD, Gu HY, Zhao L, Wu ZQ: Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol. 2006, 99: 178-84. 10.1111/j.1742-7843.2006.pto_485.x.CrossRefPubMed Guo QL, Qi Q, You QD, Gu HY, Zhao L, Wu ZQ: Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol. 2006, 99: 178-84. 10.1111/j.1742-7843.2006.pto_485.x.CrossRefPubMed
28.
go back to reference Zhou ZT, Wang JW: Phase I human tolerability trial of gambogic acid. Chin J New Drugs. 2007, 16: 79-82. Zhou ZT, Wang JW: Phase I human tolerability trial of gambogic acid. Chin J New Drugs. 2007, 16: 79-82.
29.
go back to reference Hahnvajanawong C, Boonyanugomol W, Nasomyon T, Loilome W, Namwat N, Anantachoke N, Tassaneeyakul W, Sripa B, Namwat W, Reutrakul V: Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines. World J Gastroenterol. 2010, 16: 2235-43. 10.3748/wjg.v16.i18.2235.CrossRefPubMedCentralPubMed Hahnvajanawong C, Boonyanugomol W, Nasomyon T, Loilome W, Namwat N, Anantachoke N, Tassaneeyakul W, Sripa B, Namwat W, Reutrakul V: Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines. World J Gastroenterol. 2010, 16: 2235-43. 10.3748/wjg.v16.i18.2235.CrossRefPubMedCentralPubMed
30.
go back to reference Hahnvajanawong C, Ketnimit S, Pattanapanyasat K, Anantachoke N, Sripa B, Pinmai K, Seubwai W, Reutrakul V: Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle arrest of cholangiocarcinoma cell lines by isomorellin. Biol Pharm Bull. 2012, 35: 1914-25.PubMed Hahnvajanawong C, Ketnimit S, Pattanapanyasat K, Anantachoke N, Sripa B, Pinmai K, Seubwai W, Reutrakul V: Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle arrest of cholangiocarcinoma cell lines by isomorellin. Biol Pharm Bull. 2012, 35: 1914-25.PubMed
31.
go back to reference Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994, 86: 1517-24. 10.1093/jnci/86.20.1517.CrossRefPubMed Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994, 86: 1517-24. 10.1093/jnci/86.20.1517.CrossRefPubMed
32.
go back to reference Chou TC, Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983, 4: 450-4.CrossRef Chou TC, Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983, 4: 450-4.CrossRef
33.
go back to reference Perkins ND: The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci. 2000, 25: 434-40. 10.1016/S0968-0004(00)01617-0.CrossRefPubMed Perkins ND: The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci. 2000, 25: 434-40. 10.1016/S0968-0004(00)01617-0.CrossRefPubMed
34.
go back to reference Yang PM, Huang WC, Lin YC, Huang WY, Wu HA, Chen WL, Chang YF, Chou CW, Tzeng CC, Chen YL, Chen CC: Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J Cell Mol Med. 2010, 14: 687-98.CrossRefPubMedCentralPubMed Yang PM, Huang WC, Lin YC, Huang WY, Wu HA, Chen WL, Chang YF, Chou CW, Tzeng CC, Chen YL, Chen CC: Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J Cell Mol Med. 2010, 14: 687-98.CrossRefPubMedCentralPubMed
35.
go back to reference Huang H, Chen D, Li S, Li X, Liu N, Lu X, Liu S, Zhao K, Zhao C, Guo H, Yang C, Zhou P, Dong X, Zhang C, Guanmei , Dou QP, Liu J: Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011, 301: 221-8. 10.1016/j.canlet.2010.12.015.CrossRefPubMedCentralPubMed Huang H, Chen D, Li S, Li X, Liu N, Lu X, Liu S, Zhao K, Zhao C, Guo H, Yang C, Zhou P, Dong X, Zhang C, Guanmei , Dou QP, Liu J: Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011, 301: 221-8. 10.1016/j.canlet.2010.12.015.CrossRefPubMedCentralPubMed
36.
go back to reference Reutrakul V, Anantachoke N, Pohmakotr M, Jaipetch T, Sophasan S, Yoosook C, Kasisit J, Napaswat C, Santisuk T, Tuchinda P: Cytotoxic and anti-HIV-1 caged xanthones from the resin and fruits of Garcinia hanburyi. Planta Med. 2007, 73: 33-40. 10.1055/s-2006-951748.CrossRefPubMed Reutrakul V, Anantachoke N, Pohmakotr M, Jaipetch T, Sophasan S, Yoosook C, Kasisit J, Napaswat C, Santisuk T, Tuchinda P: Cytotoxic and anti-HIV-1 caged xanthones from the resin and fruits of Garcinia hanburyi. Planta Med. 2007, 73: 33-40. 10.1055/s-2006-951748.CrossRefPubMed
37.
go back to reference Wu ZQ, Guo QL, You QD, Zhao L, Gu HY: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004, 27: 1769-74. 10.1248/bpb.27.1769.CrossRefPubMed Wu ZQ, Guo QL, You QD, Zhao L, Gu HY: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004, 27: 1769-74. 10.1248/bpb.27.1769.CrossRefPubMed
38.
go back to reference Anuszewska E, Chlopkiewicz B, Gruber B, Marczewska J, Priebe W, Skurzak H: Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Pol Pharm. 2006, 63 (4): 321-4.PubMed Anuszewska E, Chlopkiewicz B, Gruber B, Marczewska J, Priebe W, Skurzak H: Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Pol Pharm. 2006, 63 (4): 321-4.PubMed
39.
go back to reference Chen ST, Pan TL, Tsai YC, Huang CM: Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 2002, 181: 95-107. 10.1016/S0304-3835(02)00025-3.CrossRefPubMed Chen ST, Pan TL, Tsai YC, Huang CM: Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 2002, 181: 95-107. 10.1016/S0304-3835(02)00025-3.CrossRefPubMed
40.
go back to reference Hortobagyi GN: Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr. 2001, 30: 72-9.CrossRefPubMed Hortobagyi GN: Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr. 2001, 30: 72-9.CrossRefPubMed
41.
go back to reference Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R: Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002, 8: 3512-9.PubMed Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R: Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002, 8: 3512-9.PubMed
42.
go back to reference Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969, 11: 1101-10. 10.1002/bit.260110607.CrossRefPubMed Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969, 11: 1101-10. 10.1002/bit.260110607.CrossRefPubMed
43.
go back to reference Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 2002, 53: 615-27. 10.1146/annurev.med.53.082901.103929.CrossRefPubMed Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 2002, 53: 615-27. 10.1146/annurev.med.53.082901.103929.CrossRefPubMed
44.
go back to reference Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003, 22: 7414-30. 10.1038/sj.onc.1206945.CrossRefPubMed Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003, 22: 7414-30. 10.1038/sj.onc.1206945.CrossRefPubMed
46.
go back to reference Bras M, Queenan B, Susin SA: Programmed cell death via mitochondria: different modes of dying. Biochemistry (Mosc). 2005, 70: 231-9. 10.1007/s10541-005-0105-4.CrossRef Bras M, Queenan B, Susin SA: Programmed cell death via mitochondria: different modes of dying. Biochemistry (Mosc). 2005, 70: 231-9. 10.1007/s10541-005-0105-4.CrossRef
47.
go back to reference Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and −7. Biochemistry. 2001, 40: 1117-23. 10.1021/bi001603q.CrossRefPubMed Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and −7. Biochemistry. 2001, 40: 1117-23. 10.1021/bi001603q.CrossRefPubMed
48.
49.
go back to reference Cusack JC, Liu R, Baldwin AS: NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist Updat. 1999, 2: 271-3. 10.1054/drup.1999.0094.CrossRefPubMed Cusack JC, Liu R, Baldwin AS: NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist Updat. 1999, 2: 271-3. 10.1054/drup.1999.0094.CrossRefPubMed
50.
go back to reference Naus P, Henson R, Bleeker G, Wehbe H, Meng F, Patel T: Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol. 2007, 46: 222-9. 10.1016/j.jhep.2006.08.012.CrossRefPubMedCentralPubMed Naus P, Henson R, Bleeker G, Wehbe H, Meng F, Patel T: Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol. 2007, 46: 222-9. 10.1016/j.jhep.2006.08.012.CrossRefPubMedCentralPubMed
51.
go back to reference Quan F, Pan C, Ma Q, Zhang S, Yan L: Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother. 2008, 62: 622-9. 10.1016/j.biopha.2008.07.089.CrossRefPubMed Quan F, Pan C, Ma Q, Zhang S, Yan L: Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother. 2008, 62: 622-9. 10.1016/j.biopha.2008.07.089.CrossRefPubMed
52.
go back to reference Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y: Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology. 2006, 44 (4): 1025-38. 10.1002/hep.21330.CrossRefPubMed Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y: Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology. 2006, 44 (4): 1025-38. 10.1002/hep.21330.CrossRefPubMed
53.
go back to reference Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013, 45 (12): 1474-8. 10.1038/ng.2806.CrossRefPubMed Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013, 45 (12): 1474-8. 10.1038/ng.2806.CrossRefPubMed
54.
go back to reference Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 2005, 11: 3392-7.CrossRefPubMedCentralPubMed Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 2005, 11: 3392-7.CrossRefPubMedCentralPubMed
55.
go back to reference Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakul C, Soonthornchareon N, Hahnvajanawong C: Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World J Gastroenterol. 2008, 14: 1491-7. 10.3748/wjg.14.1491.CrossRefPubMedCentralPubMed Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakul C, Soonthornchareon N, Hahnvajanawong C: Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World J Gastroenterol. 2008, 14: 1491-7. 10.3748/wjg.14.1491.CrossRefPubMedCentralPubMed
56.
go back to reference Ribble D, Goldstein NB, Norris DA, Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 2005, 5: 12-10.1186/1472-6750-5-12.CrossRefPubMedCentralPubMed Ribble D, Goldstein NB, Norris DA, Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 2005, 5: 12-10.1186/1472-6750-5-12.CrossRefPubMedCentralPubMed
Metadata
Title
Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines
Authors
Chariya Hahnvajanawong
Wareeporn Wattanawongdon
Chariya Chomvarin
Natthinee Anantachoke
Sakawrat Kanthawong
Banchob Sripa
Vichai Reutrakul
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-68

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine